Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23337433 | 0.77 | BRD4 (0.34) | — | |
| SCHEMBL23336561 | 0.72 | IDH1 (0.35) | KCNH2IDH1GRM5 | |
| SCHEMBL12386590 | 0.70 | AADAT (0.40) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL9252869 | 0.68 | ADAM17 (0.45) | P2RX3IDH1GRM5GRM1 | |
| SCHEMBL31060463 | 0.68 | KCNH2 (0.34) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL3640565 | 0.68 | KCNH2 (0.34) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL23471447 | 0.68 | GRM5 (0.38) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL16478074 | 0.66 | KCNH2 (0.38) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL4371798 | 0.66 | KCNH2 (0.38) | P2RX3KCNH2IDH1GRM5GRM1 | |
| SCHEMBL25913039 | 0.66 | MAPK1 (0.38) | P2RX3KCNH2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BTK, CDK2, SYK | P2RX3 337/4885KCNH2 1206/4885IDH1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.